Johnson & Johnson May Be Forced To License Stents Patents To Complete Major Acquisition

Law360, New York (August 29, 2005, 12:00 AM EDT) -- The European Commission ruled this week Johnson & Johnson may need to license Guidant Corp.’s patents, which are held up in litigation, before acquisition of Guidant will be granted final approval.

The $25 billion dollar cash and stock deal would be the largest ever in the medical device industry and biggest in the 118-year history of Johnson & Johnson, maker of drugs, baby products, orthopedic and other health products.

Johnson & Johnson and Guidant are active worldwide in vascular medical devices, with their products used to...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.